Treatment Strategy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Gastroenterol Clin North Am. 2015 Sep;44(3):649-60. doi: 10.1016/j.gtc.2015.05.012. Epub 2015 Jun 23.

Abstract

Recent trends and current knowledge on the diagnosis and treatment strategy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma are reviewed. Helicobacter pylori infection plays the causative role in the pathogenesis, and H pylori eradication is the first-line treatment of this disease, which leads to complete remission in 60% to 90% of cases. A Japanese multicenter study confirmed that the long-term outcome of gastric MALT lymphoma after H pylori eradication is excellent. Treatment strategies for patients not responding to H pylori eradication including "watch and wait" strategy, radiotherapy, chemotherapy, rituximab immunotherapy, and combination of these should be tailored in consideration of the disease extent in each patient.

Keywords: Chemotherapy; Gastric lymphoma; Helicobacter pylori; MALT lymphoma; Radiotherapy; Rituximab.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Combined Modality Therapy
  • Helicobacter Infections / complications*
  • Helicobacter Infections / drug therapy
  • Helicobacter pylori*
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / diagnosis
  • Lymphoma, B-Cell, Marginal Zone / microbiology
  • Lymphoma, B-Cell, Marginal Zone / therapy*
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / microbiology
  • Stomach Neoplasms / therapy*

Substances

  • Anti-Bacterial Agents